Literature DB >> 12440705

Transport characteristics of HL-1 cells: a new model for the study of adenosine physiology in cardiomyocytes.

Naz Chaudary1, Iirina Shuralyova, Tamar Liron, Gary Sweeney, Imogen R Coe.   

Abstract

Adenosine is a physiologically important nucleoside in the cardiovascular system where it can act as a cardioprotectant and modulator of energy usage. Adenosine transporters (ATs) modulate cellular adenosine levels, which, in turn, can affect a number of processes such as receptor activation and glucose uptake, but their role in cardiac physiology is poorly understood. Therefore, we have developed a new cell model by determining various adenosine-related characteristics of HL-1, an immortalized atrial cardiomyocyte murine cell line. Adenosine uptake in HL-1 cells is sodium independent, saturable, and inhibitable by nucleoside transport inhibitors (nitrobenzylthioinosine (NBTI), dipyridamole, dilazep). Reverse transcription--polymerase chain reaction analysis confirmed that HL-1 cells possess mouse equilibrative nucleoside transporters 1 and 2 (mENT1, mENT2) and kinetic analyses indicate moderate-affinity (Km = 51.3 +/- 12.9 microM), NBTI-sensitive adenosine transport. NBTI binds at a high-affinity single site (B(max) = 520 +/- 10 fmol/mg protein, Kd = 0.11 +/- 0.04 nM, 1.6 x 10(5) NBTI-binding sites/cell). HL-1 cells possess adenosine receptor, metabolic enzyme, protein kinase C isoform, and insulin-stimulated glucose transport profiles that match normal mouse heart. Therefore, HL-1 is an excellent model to study ATs within cardiomyocytes and the first model for evaluating in detail the role of the ATs in modulating effects of adenosine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12440705     DOI: 10.1139/o02-143

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  7 in total

1.  Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor.

Authors:  Athena M Keene; Ramachandran Balasubramanian; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

2.  Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells).

Authors:  C Alfarano; L Sartiani; C Nediani; E Mannucci; A Mugelli; E Cerbai; L Raimondi
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

3.  The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity.

Authors:  Azza Ramadan; Zlatina Naydenova; Katarina Stevanovic; Jennifer B Rose; Imogen R Coe
Journal:  Purinergic Signal       Date:  2013-10-27       Impact factor: 3.765

4.  Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection.

Authors:  Jennifer B Rose; Zlatina Naydenova; Andrew Bang; Megumi Eguchi; Gary Sweeney; Doo-Sup Choi; James R Hammond; Imogen R Coe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-24       Impact factor: 4.733

Review 5.  Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury?

Authors:  Cui Yang; George P H Leung
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

6.  N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function.

Authors:  Alex Bicket; Imogen R Coe
Journal:  Biosci Rep       Date:  2016-08-31       Impact factor: 3.840

7.  Mapping metabolic changes by noninvasive, multiparametric, high-resolution imaging using endogenous contrast.

Authors:  Zhiyi Liu; Dimitra Pouli; Carlo A Alonzo; Antonio Varone; Sevasti Karaliota; Kyle P Quinn; Karl Münger; Katia P Karalis; Irene Georgakoudi
Journal:  Sci Adv       Date:  2018-03-07       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.